Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Common Equity (2016 - 2025)

Macrogenics (MGNX) has disclosed Common Equity for 14 consecutive years, with $55.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 52.1% to $55.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.6 million, a 52.1% decrease, with the full-year FY2025 number at $55.6 million, down 52.1% from a year prior.
  • Common Equity was $55.6 million for Q4 2025 at Macrogenics, down from $67.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $350.5 million in Q1 2021 to a low of $55.6 million in Q4 2025.
  • A 5-year average of $144.4 million and a median of $142.0 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 83.94% in 2021, then crashed 66.29% in 2024.
  • Macrogenics' Common Equity stood at $239.6 million in 2021, then tumbled by 40.73% to $142.0 million in 2022, then rose by 7.46% to $152.6 million in 2023, then dropped by 23.95% to $116.1 million in 2024, then crashed by 52.1% to $55.6 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Common Equity are $55.6 million (Q4 2025), $67.0 million (Q3 2025), and $79.1 million (Q1 2025).